Enzymatic synthesis of key RNA therapeutic building blocks using simple phosphate donors

The rapid emergence of RNA therapeutics has highlighted the need for more efficient, scalable and sustainable methods for their manufacture. Biocatalytic approaches hold particular promise, but rely on a secure, sustainable and low-cost supply of nucleoside triphosphate (NTP) building blocks, including those containing chemical modifications. Here we report the development of a biocatalytic approach and engineered enzymes to convert widely available nucleosides into NTPs featuring pharmaceutically relevant modifications using inexpensive phosphate donors. Importantly our strategy obviates the need for ATP as a phosphate donor that complicates NTP isolation using existing methods. To showcase the utility of our approach, we employ an engineered acid phosphatase, polyphosphate kinase and acetate kinase to produce 2'-O-methoxyethyl-ATP (2'-MOE-ATP) and 2'-fluoro-ATP, key building blocks of commercial therapeutics. Finally, we show that crude NTPs from our process can be used directly in enzymatic oligonucleotide synthesis, obviating the need for costly NTP isolation or purification steps.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2025-12-17
DOI
https://doi.org/10.1038/s41467-025-67366-4
Citations
1
Primary Topic
Biochemical and Molecular Research
Type
article
Field-Weighted Citation Impact
0.81

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Enzymatic synthesis of key RNA therapeutic building blocks using simple phosphate donors

Caecilie M. M. Benckendorff, Charlotte Morrill, Ying Zhuo, Richard Obexer et al.
1 citations
Nature Communications
Biochemical and Molecular Research
0.81
article

Enzymatic synthesis of key RNA therapeutic building blocks using simple phosphate donors

Caecilie M. M. Benckendorff, Charlotte Morrill, Ying Zhuo, Richard Obexer, Gavin John Miller, Mary Ortmayer, James Finnigan, Simon J. Charnock, Sarah L. Lovelock, Aisling Ní Cheallaigh, Colin Levy, Nicholas J. Turner, Qinglong Meng, Sasha R. Derrington, Annette Egerström
article en
1 citations

Abstract

The rapid emergence of RNA therapeutics has highlighted the need for more efficient, scalable and sustainable methods for their manufacture. Biocatalytic approaches hold particular promise, but rely on a secure, sustainable and low-cost supply of nucleoside triphosphate (NTP) building blocks, including those containing chemical modifications. Here we report the development of a biocatalytic approach and engineered enzymes to convert widely available nucleosides into NTPs featuring pharmaceutically relevant modifications using inexpensive phosphate donors. Importantly our strategy obviates the need for ATP as a phosphate donor that complicates NTP isolation using existing methods. To showcase the utility of our approach, we employ an engineered acid phosphatase, polyphosphate kinase and acetate kinase to produce 2'-O-methoxyethyl-ATP (2'-MOE-ATP) and 2'-fluoro-ATP, key building blocks of commercial therapeutics. Finally, we show that crude NTPs from our process can be used directly in enzymatic oligonucleotide synthesis, obviating the need for costly NTP isolation or purification steps.

Nature CommunicationsVol. 17(1)
University of Manchester (GB), Prozomix (United Kingdom) (GB), Keele University (GB)
UK Research and Innovation, Medical Research Council
Openalex Percentile: Top 21%
Biochemical and Molecular Research
0.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.